Zusammenfassung
Der vorliegende Artikel geht auf Wirksamkeit und Antigenität der drei auf dem Markt
verfügbaren Botulinumtoxine vom Typ A bzw. B (Dysport, Botox, Neurobloc) ein. Insbesondere
der Darstellung des Wirkungsäquivalents wird besondere Aufmerksamkeit gewidmet (Botox
: Dysport : Neurobloc = 1 : 3 : 30 - 100).
Abstract
This article focusses on potency and antigenic properties of the three botulinum toxin
preparations available (Dysport, Botox, Neurobloc). In clinical practice, the equivalent
dosages are of special importance (Botox : Dysport : Neurobloc = 1 : 3 : 30 - 100).
Key words
Botulinum toxin - A, B, antigenic property - Equivalent dosage
Literatur
- 1 Aoki R, Merlino G F, Spanoyannis A F, Wheeler L A. Preclinical Update on Botox (Botulinum
Toxin Type A Purified Neurotoxin Complex) and Other Neurotoxin Preparations. Proc
4th European Botulinum toxin Symposium 1999: 2-3
- 2 Benecke R.
Botulinum toxin for spasms and spasticity in the lower extremities. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. New York; Marcel Dekker
1994: 557-565
- 3
Bigalke H, Shoer L.
Clostridial neurotoxins.
Handbook Exp Pharm.
2000;
145
407-444
- 4
Bigalke H, Wohlfarth K, Irmer A, Dengler R.
Botulinum A toxin: Dysport Improvement of biological availability.
Experimental Neurology.
2001;
168
162-170
- 5
Brin M F, Fahn S, Moskowitz C, Friedmann A.
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial
spasm.
Mov Disord.
1987;
2
237-254
- 6
Bülbring E.
Observations on the isolated phrenic nerve diaphragm preparation in the rat.
Br J Pharmacol.
1946;
1
38-61
- 7
Durif F.
Clinical Bioequivalence of the Current Preparations of botulinum Toxin.
Eur Neurol.
1995;
2
17-19
- 8
Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H.
Botulinum A Therapy: Neutralising and Nonneutralising Antibodies - Therapeutic Consequences.
Experimental Neurology.
1997;
147
96-102
- 9
Goodnough M C, Johnson E A.
Stabilising of Botulinum Toxin Type A During Lyophilisation.
Appl Environ Microbiol.
1992;
58
3426-3428
- 10
Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K,
Oguma K.
Molecular composition of Clostridium botulinum type A progenitor toxins.
Infect Immun.
1996;
64
1589-1594
- 11
Hambleton P, Pickett A M.
Potency Equivalence of Botulinum Toxin Preparations.
J R Soc Med.
1994;
87
719
- 12
Nuessgen Z, Roggenkaemper P.
Comparison of two Botulinum-Toxin Preparations in the Treatment of Essential Blepharospasm.
Graefe's Arch Clin Exp Ophthalmol.
1997;
235
197-199
- 13
Poewe W, Schelosky I, Kleedorfer B.
Treatment of spasmodic torticollis with local injections of botulinum toxin. One year
follow-up in 37 patients.
J Neurol.
1992;
53
21-25
- 14
Rollnik J, Matzke M, Wohlfarth K, Dengler R, Bigalke H.
Low dose treatment of cervical dystonia, Blepharospasm and facial hemispasm with albumin-dilutet
botulinum toxin type A under EMG guidance.
Europ Neurol.
2000;
43
9-12
- 15 Schantz E, Johnson E A.
Preparation and Characterisation of Botulinum Toxin Type A for Human Treatment. In: Jancovic J, Hallett M (eds) Therapy with Botulinum Toxin. New York, Basel, Hongkong;
Marcel Dekker 1994: 41-49
- 16
Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre E C.
Five-year experience in the treatment of focal movement disorders with low-dose Dysport
botulinum toxin.
Muscle Nerve.
1995;
18
720-729
- 17
Wohlfarth K, Göschel H, Frevert J, Dengler R, Bigalke H.
Botulinum A Toxins: Units Versus Units.
Naunyn-Schmiedeberg's Arch Pharmacol.
1997;
355
335-340
- 18
Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P.
Botulinum Antibodies in Dystonic Patients Treated with Type A Botulinum Toxin: Frequency
and Significance.
Neurology.
1993;
43
1715-1718
Hans Bigalke
Institut für Toxikologie · Medizinische Hochschule Hannover
30625 Hannover
